# Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

> **NCT05503953** · PHASE3 · UNKNOWN · sponsor: **Ahn-Gook Pharmaceuticals Co.,Ltd** · enrollment: 306 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** AGSAVI
- **DRUG:** AGLS

## Key facts

- **NCT ID:** NCT05503953
- **Lead sponsor:** Ahn-Gook Pharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-05
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-07-31
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2022-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503953, "Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05503953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*